Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-15 · accession 0001819790-25-000047 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-18 | 2025-03-15 | TARS | Farrow Jeffrey S | See Remarks | M - OptEx | — | +8,019 | 26.2K | +44% | — |
| D | 2025-03-18 | 2025-03-17 | TARS | Farrow Jeffrey S | See Remarks | M - OptEx | $0.00 | -8,019 | 24.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-15 | M | A | 8,019 | — | 26,155 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). |
| 2 | Derivative | Restricted Stock Units | 2025-03-17 | M | D | 8,019 | $0.00 | 24,060 | D | — · — to — | 8,019 Common Stock | (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F3) RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. |